Clinical Trial Update: ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL [Phase 3]

View source ↗

Summary

A Phase 3 global trial (ROCKET-CLL) comparing rocbrutinib to pirtobrutinib in patients previously treated with covalent BTK inhibitors and with relapsed/refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Rocbrutinib (rocbrutinib)

Snippet

Sponsor: Newave Pharmaceutical Inc | Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Status: NOT_YET_RECRUITING